We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott Gains in Nutrition With Adult Segment Leading Growth
Read MoreHide Full Article
Key Takeaways
Abbott's Nutrition business expands on strong global demand despite some softness in pediatrics.
ABT's adult Nutrition grew 6.6% organically in Q2 2025, leading overall segment growth.
ABT's Ensure and Glucerna continue to fuel demand, while Similac remains strong in the U.S. market.
Abbott Laboratories’ (ABT - Free Report) Nutrition business has consistently demonstrated strong growth and market share gains. This segment offers a broad line of pediatric and adult nutritional products. Despite some ongoing softness in a few international markets for pediatric products, the overall Nutrition business is expanding on strong global demand for the company’s adult nutrition offerings that provide a combination of high protein and low sugar to help people optimize their health and wellness.
Post the COVID-19 pandemic, people have become more conscious about the impact of an unhealthy lifestyle. This had a positive impact on the nutritional supplements industry. In addition, the rising rates of non-communicable diseases have led to a quicker adoption of nutritional supplements aimed at improving overall health. Based on these factors, analysts predicted the global nutritional supplements market size to reach $704.28 billion by 2030, at a CAGR of 6.42% from 2025 to 2030 (per Grand View Research).
The segment continues to benefit from strong demand for Ensure and Glucerna, Abbott’s market-leading brands that support complete and balanced nutrition and help manage dietary requirements for people with diabetes. Within Pediatric Nutrition, Abbott enjoyed continued strength in the United States, where the Similac brand remains the top choice for American parents. Furthermore, during the second quarter of 2025, the company reported mid-single-digit organic growth within this business, led by 6.6% organic growth in Adult Nutrition.
Offerings by ABT’s Peers in the Nutrition Space
Nestles’ (NSRGY - Free Report) Nutrition business provides science-based products and solutions for mothers, babies and children. Additionally, its Health Science business supports healthier lives by offering an extensive portfolio of science-based consumer care and medical nutrition. Nestle’s nutrition portfolio covers every life stage, from infant formula to medical nutrition and adult nutrition. Infant and Child Nutrition products include NAN (infant formulas) and Cerelac (infant cereals), among many others. The Adult & Performance Nutrition portfolio includes products like Boost (nutritional drinks for adults and the elderly) and Vital Proteins (collagen-based supplements).
Danone (DANOY - Free Report) provides specialized nutrition with its portfolio divided into Early Life Nutrition and Medical Nutrition. In the early life category, Danone offers a wide range of infant and child nutrition products under well-known brands such as Aptamil, Nutrilon, Cow & Gate, and Bledina, covering infant formula, follow-on formula and baby food. Through its Nutricia division, Danone offers products like Neocate (for cow’s milk protein allergy), Fortimel and Fortisip (oral nutritional supplements), and specialized enteral feeding formulas such as Nutrison, Nutrini and Peptisorb. Additionally, Danone provides condition-specific solutions like FortiCare for oncology patients and Diasip for those with diabetes.
ABT Price Performance
Year to date, Abbott shares have surged 16.5%, outperforming the industry’s 5.9% growth. The S&P 500 composite grew 9.6% in the same period.
Image Source: Zacks Investment Research
Discounted Valuation
ABT currently trades at a forward 12-month Price-to-Sales (P/S) of 4.89X compared with the industry average of 5.56X.
Image Source: Zacks Investment Research
ABT Stock Estimate Trend
In the past 30 days, ABT’s EPS estimate has moved south 0.2% for 2025.
Image: Bigstock
Abbott Gains in Nutrition With Adult Segment Leading Growth
Key Takeaways
Abbott Laboratories’ (ABT - Free Report) Nutrition business has consistently demonstrated strong growth and market share gains. This segment offers a broad line of pediatric and adult nutritional products. Despite some ongoing softness in a few international markets for pediatric products, the overall Nutrition business is expanding on strong global demand for the company’s adult nutrition offerings that provide a combination of high protein and low sugar to help people optimize their health and wellness.
Post the COVID-19 pandemic, people have become more conscious about the impact of an unhealthy lifestyle. This had a positive impact on the nutritional supplements industry. In addition, the rising rates of non-communicable diseases have led to a quicker adoption of nutritional supplements aimed at improving overall health. Based on these factors, analysts predicted the global nutritional supplements market size to reach $704.28 billion by 2030, at a CAGR of 6.42% from 2025 to 2030 (per Grand View Research).
The segment continues to benefit from strong demand for Ensure and Glucerna, Abbott’s market-leading brands that support complete and balanced nutrition and help manage dietary requirements for people with diabetes. Within Pediatric Nutrition, Abbott enjoyed continued strength in the United States, where the Similac brand remains the top choice for American parents. Furthermore, during the second quarter of 2025, the company reported mid-single-digit organic growth within this business, led by 6.6% organic growth in Adult Nutrition.
Offerings by ABT’s Peers in the Nutrition Space
Nestles’ (NSRGY - Free Report) Nutrition business provides science-based products and solutions for mothers, babies and children. Additionally, its Health Science business supports healthier lives by offering an extensive portfolio of science-based consumer care and medical nutrition. Nestle’s nutrition portfolio covers every life stage, from infant formula to medical nutrition and adult nutrition. Infant and Child Nutrition products include NAN (infant formulas) and Cerelac (infant cereals), among many others. The Adult & Performance Nutrition portfolio includes products like Boost (nutritional drinks for adults and the elderly) and Vital Proteins (collagen-based supplements).
Danone (DANOY - Free Report) provides specialized nutrition with its portfolio divided into Early Life Nutrition and Medical Nutrition. In the early life category, Danone offers a wide range of infant and child nutrition products under well-known brands such as Aptamil, Nutrilon, Cow & Gate, and Bledina, covering infant formula, follow-on formula and baby food. Through its Nutricia division, Danone offers products like Neocate (for cow’s milk protein allergy), Fortimel and Fortisip (oral nutritional supplements), and specialized enteral feeding formulas such as Nutrison, Nutrini and Peptisorb. Additionally, Danone provides condition-specific solutions like FortiCare for oncology patients and Diasip for those with diabetes.
ABT Price Performance
Year to date, Abbott shares have surged 16.5%, outperforming the industry’s 5.9% growth. The S&P 500 composite grew 9.6% in the same period.
Image Source: Zacks Investment Research
Discounted Valuation
ABT currently trades at a forward 12-month Price-to-Sales (P/S) of 4.89X compared with the industry average of 5.56X.
Image Source: Zacks Investment Research
ABT Stock Estimate Trend
In the past 30 days, ABT’s EPS estimate has moved south 0.2% for 2025.
Image Source: Zacks Investment Research
ABT stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.